Schwannomas are tumors formed by proliferation of dedifferentiated Schwann cells. Patients with neurofibromatosis 2 (NF2) and schwannomatosis develop multiple schwannomas in peripheral and cranial nerves. Although benign, these tumors can cause extreme pain and compromise sensory/motor functions, including hearing and vision. At present, surgical resection is the main treatment modality, but it can be problematic because of tumor inaccessibility and risk of nerve damage. We have explored gene therapy for schwannomas, using a model in which immortalized human NF2 schwannoma cells expressing a fluorescent protein and luciferase are implanted in the sciatic nerve of nude mice. Direct injection of an adeno-associated virus (AAV) serotype 1 vector encoding caspase-1 (ICE) under the Schwann-cell specific promoter, P0, leads to regression of these tumors with essentially no vector-mediated neuropathology, and no changes in sensory or motor function. In a related NF2 xenograft model designed to cause measurable pain behavior, the same gene therapy leads to tumor regression and concordant resolution of tumor-associated pain. This AAV1-P0-ICE vector holds promise for clinical treatment of schwannomas by direct intratumoral injection to achieve reduction in tumor size and normalization of neuronal function.
Get full access to this article
View all access options for this article.
References
1.
AgarwalN., PacherP., TegederI.et al.2007. Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors. Nat. Neurosci., 10:870–879.
2.
AntinheimoJ., SankilaR., CarpénO.et al.2000. Population-based analysis of sporadic and type 2 neurofibromatosis-associated meningiomas and schwannomas. Neurology, 54:71–76.
3.
BalajL., LessardR., DaiL.et al.2011. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun., 2:180.
4.
BaserM.E., FriedmanJ.M., EvansD.G.2006. Increasing the specificity of diagnostic criteria for schwannomatosis. Neurology, 66:730–732.
5.
BowersW.J., BreakefieldX.O., Sena-EstevesM.2011. Genetic therapy for the nervous system. Hum. Mol. Genet., 20:R28–R41.
6.
BroekmanM.L., ComerL.A., HymanB.T., Sena-EstevesM.2006. Adeno-associated virus vectors serotyped with AAV8 capsid are more efficient than AAV-1 or −2 serotypes for widespread gene delivery to the neonatal mouse brain. Neuroscience, 138:501–510.
7.
BrownA.M., LemkeG.1997. Multiple regulatory elements control transcription of the peripheral myelin protein zero gene. J. Biol. Chem., 272:28939–28947.
8.
ChenQ., PetoC.A., SheltonG.D.et al.2009. Loss of modifier of cell adhesion reveals a pathway leading to axonal degeneration. J. Neurosci., 29:118–130.
9.
Di StasiA., TeyS.K., DottiG.et al.2011. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med., 365:1673–1683.
10.
EberlingJ.L., JagustW.J., ChristineC.W.et al.2008. Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology, 70:1980–1983.
11.
EichlerF.S., HornemannT., McCampbellA.et al.2009. Overexpression of the wild-type SPT1 subunit lowers desoxysphingolipid levels and rescues the phenotype of HSAN1. J. Neurosci., 29:14646–14651.
12.
FriedlanderR.M.2000. Role of caspase 1 in neurologic disease. Arch. Neurol., 57:1273–1276.
13.
FurlanR., MartinoG., GalbiatiF.et al.1999. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J. Immunol., 163:2403–2409.
14.
GrayS.J., FotiS.B., SchwartzJ.W.et al.2011. Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. Hum. Gene Ther., 22:1143–1153.
15.
HadfieldK.D., NewmanW.G., BowersN.L.et al.2008. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J. Med. Genet., 45:332–339.
16.
HarrisJ.E., SheeanP.M., GleasonP.M.et al.2012. Publishing nutrition research: A review of multivariate techniques. 2. Analysis of variance. J. Acad. Nutr. Diet., 112:90–98.
17.
HuangJ.H., SimonS.L., NagpalS.et al.2004. Management of patients with schwannomatosis: Report of six cases and review of the literature. Surg. Neurol., 62:353–361.
18.
HulsebosT.J., PlompA.S., WoltermanR.A.et al.2007. Germline mutation of INI1/SMARCB1 in familial schwannomatosis. Am. J. Hum. Genet., 80:805–810.
19.
HungG., LiX., FaudoaR.et al.2002. Establishment and characterization of a schwannoma cell line from a patient with neurofibromatosis 2. Int. J. Oncol., 20:475–482.
20.
JacobyL.B., JonesD., DavisK.et al.1997. Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am. J. Hum. Genet., 61:1293–1302.
21.
JessenK.R., MirskyR.2005. The origin and development of glial cells in peripheral nerves. Nat. Rev. Neurosci., 6:671–682.
22.
JuanT.S., McNieceI.K., JenkinsN.A.et al.1996. Molecular characterization of mouse and rat CPP32 β gene encoding a cysteine protease resembling interleukin-1β converting enzyme and CED-3. Oncogene, 13:749–755.
23.
KaplittM.G., FeiginA., TangC.et al.2007. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: An open label, phase I trial. Lancet, 369:2097–2105.
24.
KirschbaumK.M., HiemkeC., SchmittU.2009. Rotarod impairment: Catalepsy-like screening test for antipsychotic side effects. Int. J. Neurosci., 119:1509–1522.
25.
LamkanfiM., DixitV.M.2009. Inflammasomes: Guardians of cytosolic sanctity. Immunol. Rev., 227:95–105.
26.
LeeM., BrennanA., BlanchardA.et al.1997. P0 is constitutively expressed in the rat neural crest and embryonic nerves and is negatively and positively regulated by axons to generate non-myelin-forming and myelin-forming Schwann cells, respectively. Mol. Cell. Neurosci., 8:336–350.
27.
LentzT.B., GrayS.J., SamulskiR.J.2012. Viral vectors for gene delivery to the central nervous system. Neurobiol. Dis., 48:179–188.
28.
Lu-EmersonC., PlotkinS.R.2009. The neurofibromatosis. 2. NF2 and schwannomatosis. Rev. Neurol. Dis., 6:E81–E86.
29.
MaitituohetiM., LiY., WangW.et al.2011. Adeno-associated virus-mediated local delivery of LIGHT suppresses tumorigenesis in a murine cervical cancer model. J. Immunother., 34:581–587.
30.
McCartyD.M., FuH., MonahanP.E.et al.2003. Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther., 10:2112–2118.
McCownT.J.2011. Adeno-associated virus (AAV) vectors in the CNS. Curr. Gene Ther., 11:181–188.
33.
McPheeS.W., JansonC.G., LiC.et al.2006. Immune responses to AAV in a phase I study for Canavan disease. J. Gene Med., 8:577–588.
34.
MeijerD.H., MaguireC.A., LeRoyS.G., Sena-EstevesM.2009. Controlling brain tumor growth by intraventricular administration of an AAV vector encoding IFN-βCancer Gene Ther., 16:664–671.
35.
MesserliS.M., TangY., GiovanniniM.et al.2002. Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. Neoplasia, 4:501–509.
MiuraM., ZhuH., RotelloR.et al.1993. Induction of apoptosis in fibroblasts by IL-1β-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell, 75:653–660.
38.
PrabhakarS., MesserliS.M., Stemmer-RachamimovA.O.et al.2007. Treatment of implantable NF2 schwannoma tumor models with oncolytic herpes simplex virus G47ΔCancer Gene Ther., 14:460–467.
39.
PrabhakarS., BrennanG.J., MesserliS.M.et al.2010. Imaging and therapy of experimental schwannomas using HSV amplicon vector-encoding apoptotic protein under Schwann cell promoter. Cancer Gene Ther., 17:266–274.
40.
RouleauG.A., MerelP., LutchmanM.et al.1993. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature, 363:515–521.
41.
SarkarA., MitraS., MehtaS.et al.2009. Monocyte derived microvesicles deliver a cell death message via encapsulated caspase-1. PLoS One, 4:e7140.
42.
SaydamO., OzdenerG.B., SenolO.et al.2011. A novel imaging-compatible sciatic nerve schwannoma model. J. Neurosci. Methods, 195:75–77.
43.
ShenD., ZhangQ., GaoX.et al.2011. Age-related changes in myelin morphology, electrophysiological property and myelin-associated protein expression of mouse sciatic nerves. Neurosci. Lett., 502:162–167.
44.
TamaiH., MiyakeK., YamaguchiH.et al.2012. AAV-8 vector expressing IL-24 efficiently suppresses tumor growth mediated by specific mechanisms in MLL/AF4-positive ALL model mice. Blood, 119:64–71.
45.
TaylorD.D., Gercel-TaylorC.2008. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol., 110:13–21.
46.
TeschendorfC., EmonsB., MuzyczkaN.et al.2010. Efficacy of recombinant adeno-associated viral vectors serotypes 1, 2, and 5 for the transduction of pancreatic and colon carcinoma cells. Anticancer Res., 30:1931–1935.
47.
WorgallS., SondhiD., HackettN.R.et al.2008. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther., 19:463–474.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
